TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06144073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (Mandala art therapy) group
Description: Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
Study: NCT05832320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
Study: NCT05425420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone hydrochloride 0.1mg/kg
Description: Single dose of methadone hydrochloride administered via intravenous (IV)
Study: NCT06052774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical periodontal therapy
Description: Supra and Subgingival debridement for all patients except periodontally healthy individuals

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical periodontal therapy
Description: Supra and Subgingival debridement for all patients except periodontally healthy individuals
Study: NCT06341127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Oral fluoxetine daily, 2.5 to 5 mg.
Study: NCT05379959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 125 mg of MDMA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 125 mg of MDMA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 125 mg of MDMA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of MA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of MA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Participants will be given 20 mg of MA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT05443997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIYCN capacity building
Description: * MIYCN knowledge, skills, and motivation of FLWs~* Supportive supervision~* Decentralized programmatic decision-making using data~* PRI member involvement~* Availability of THR~* IYCF knowledge and practices
Study: NCT05280119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchOpen ultra-portable ultrasound device
Description: Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound device routinely used in the department.
Description: Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard ultrasound examination by an independent referent radiologist
Description: In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
Study: NCT05293275

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EaseVRx Virtual Reality Headset
Description: Virtual reality device with 360 degree visualization of various scenery and interactive modules
Study: NCT05451212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MuSK-CAART
Description: Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
Study: NCT06572514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin
Description: The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
Study: NCT06040749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual group-based handcycling
Description: Virtual group-based handcycling
Study: NCT06573775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed ultrasound
Description: treatment of myofacial trigger points with therapeutic ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release
Description: manual massage and range of motion exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: manual massage and range of motion exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: manual massage and range of motion exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lidocaine phonophoresis
Description: transdermal tranmission of lidocaine molecules via ultrasound
Study: NCT06573164

Intervention type: DRUG
Intervention: Bacillus clausii tablets（Qipian®）
Description: Take 4 tablets (0.3 mg each) orally three times daily.

Intervention type: DRUG
Intervention: conventional medication
Description: Use conventional medication as needed based on the patient's condition.

Intervention type: DRUG
Intervention: conventional medication
Description: Use conventional medication as needed based on the patient's condition.
Study: NCT06572215

Intervention type: DRUG
Intervention: Dapagliflozin
Description: On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.

Intervention type: DRUG
Intervention: Dapagliflozin
Description: On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
Study: NCT06664229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall and dementia prevention exercise
Description: The fall and dementia prevention exercise is designed as a combination of balancing and cognitive exercise and games that is conducted as a group activity. The session will be provided three times per week for six weeks for a pilot test and three times per week for 12 weeks for a main comparison study.~The fall prevention exercise involves the pressure mat based balancing exercise such as side stepping, heel or toe standing, and quarter squat. The safety bar will be placed around the mat, so that older adults with instability can hold while they follow the movements.~The cognitive exercise will concise of multiple types of cognitive tasks to train memory, numeric processing, spatial perception, and logical thinking. For example, memory task such as memorizing the series of positions on the screen and use the mat to point the positions in the right order.~At the end, older adults play games in which they use balancing movements and cognitive tasks to gain scores for their team.
Study: NCT06664476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PortCare Professional Training Program
Description: The intervention is a targeted educational program to enhance oncology nurses' skills in managing Port-A-Catheters for chemotherapy patients. It includes a preparatory phase to assess baseline knowledge and practices, followed by an implementation phase with theoretical and practical training. Theoretical sessions cover device basics and care guidelines, while practical sessions provide hands-on training on procedures like catheter insertion, flushing, and removal. This program aims to improve patient safety, reduce complications, and boost nurses' confidence in Port-A-Catheter care.
Study: NCT06664411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy
Description: Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy
Study: NCT06664736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise group performed a home-based exercise program consisting of aerobics 3 days a week with videos and strengthening and stretching exercises 2 days a week with infographics, for 8 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity
Description: The control group was advised to increase physical activity
Study: NCT06663943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313 (SC)
Description: CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Patients in the control group receive azathioprine in combination with steroid therapy.
Study: NCT06663800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ujjayi Paranayama
Description: Inhale or breathe in slowly while taking a deep, prolonged breath through both nostrils. As you inhale, attempt to tighten your throat and feel the air in your throat. Air should not come into contact with the interior of the nose. When air enters the throat, an odd sound is made. Allow the breath to be loose and easy while you slightly tighten the back of your throat and hiss lightly as you breathe in and out. The sound isn't forced, but it should be loud enough for someone to hear you if they were close. Now close your right nostril and release the breath through your left. As you exhale, try making the sound HHHHHAAAA

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Protocol
Description: Control Group will perform Deep Breathing Adhering to a FITT model protocol, with a frequency of 5 days. Intensity set at 8 repetitions, duration range from 10 to 15 minutes
Study: NCT06662981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preoparative information and education
Description: The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
Study: NCT06663488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural anesthesia
Description: The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic spinal anesthesia
Description: Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
Study: NCT06661837

Intervention type: OTHER
Intervention: Clinical examination and mobile photo
Description: Children were both clinically examined and a mobile photo was taken for assessment
Study: NCT05918952

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 Antibody Test
Description: The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap.

Intervention type: OTHER
Intervention: Short Clip videos
Description: Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.

Intervention type: OTHER
Intervention: Short Clip videos
Description: Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
Study: NCT05681299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone and lirglutide
Description: GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone
Description: GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
Study: NCT06621121

Intervention type: OTHER
Intervention: Tenecteplase
Description: The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.

Intervention type: OTHER
Intervention: Alteplase
Description: The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.
Study: NCT06620237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the Solia CSP S pacing lead for LBBAP
Description: Left bundle branch area pacing using a Solia CSP S lead
Study: NCT05681299

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
Study: NCT05679791

Intervention type: DEVICE
Intervention: Dynamometer
Description: to assses hand grip

Intervention type: DEVICE
Intervention: Dynamometer
Description: to assses hand grip
Study: NCT06033937

Intervention type: DEVICE
Intervention: PFO occlusion
Description: Patients in PFO occlusion group received PFO closure using devices.
Study: NCT05642871

Intervention type: RADIATION
Intervention: DKI and APT
Description: DKI and APT in patients with ovarian malignancy before and after treatment
Study: NCT06286319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel Cooler
Description: Device that provides cooled oxygen (between 4-8°C) directly to the lung airways along with external cooling to lung surfaces using cold preservation solutions.
Study: NCT06180993

Intervention type: BIOLOGICAL
Intervention: Nirsevimab
Description: Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study

Intervention type: BIOLOGICAL
Intervention: Nirsevimab
Description: Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study

Intervention type: BIOLOGICAL
Intervention: Nirsevimab
Description: Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
Study: NCT04992780

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-Fractionation
Description: 62.5 Gy in 25 fractions of 2.5 Gy/fraction

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Fractionation
Description: 60 Gy in 30 fractions of 2 Gy/fraction
Study: NCT05888649

Intervention type: BEHAVIORAL
Intervention: Community Clusters
Description: Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.

Intervention type: BEHAVIORAL
Intervention: Community Clusters
Description: Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.

Intervention type: BEHAVIORAL
Intervention: Community Clusters
Description: Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.

Intervention type: BEHAVIORAL
Intervention: Community Clusters
Description: Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
Study: NCT05368207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
Study: NCT04598815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g.
Study: NCT06000878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: first aid e-book
Description: interactive first aid e-book interventions
Study: NCT06285539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib
Study: NCT05239676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells
Description: The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
Study: NCT06098820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Description: Four different groups will be compared with each other in terms of vitamin D effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Description: Four different groups will be compared with each other in terms of vitamin D effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Description: Four different groups will be compared with each other in terms of vitamin D effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Description: Four different groups will be compared with each other in terms of vitamin D effect.
Study: NCT04996303

Intervention type: DRUG
Group type: OTHER
Intervention: Routine steroid administration group
Description: Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Steroid pulse therapy group
Description: Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg \~ 1g) pulse 3 days -\> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
Study: NCT06358391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TS-RF Transseptal Needle
Description: Apply radiofrequency energy to the electrode tip via the TS-RF Generator and puncture the atrial septum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BRK Transseptal Needle
Description: Cross and puncture the atrial septum with the BRK Transseptal Needle